

Contents

A Personal Foreword IX

1	Physicochemistry	1
1.1	Physicochemistry and Pharmacokinetics	2
1.2	Partition and Distribution Coefficients as Measures of Lipophilicity	2
1.3	Limitations on the Use of 1-Octanol	5
1.4	Further Understanding of $\log P$	6
1.4.1	Unraveling the Principal Contributions to $\log P$	6
1.4.2	Hydrogen Bonding	7
1.4.3	Polar Surface Area	8
1.4.4	Molecular Size and Shape	9
1.5	Alternative Lipophilicity Scales	10
1.6	Computational Systems to Determine Lipophilicity	10
1.7	Membrane Systems to Study Drug Behavior	10
1.8	Dissolution and Solubility	12
1.9	The BCS Classification and Central Role of Permeability	13
	References	15
2	Pharmacokinetics	19
2.1	Setting the Scene	20
2.2	Intravenous Administration: Volume of Distribution	21
2.3	Intravenous Administration: Clearance	22
2.4	Intravenous Administration: Clearance and Half-life	23
2.5	Intravenous Administration: Infusion	24
2.6	Oral Administration	26
2.7	Repeated Doses	27
2.8	Development of the Unbound (Free) Drug Model	29
2.9	Unbound Drug and Drug Action	29
2.10	Unbound Drug Model and Barriers to Equilibrium	32
2.11	Pharmacodynamic Models	34

2.12	Slow Offset Compounds	35
2.13	Factors Governing Unbound Drug Concentration	38
	References	40
3	Absorption	41
3.1	The Absorption Process	42
3.2	Dissolution	42
3.3	Membrane Transfer	44
3.4	Barriers to Membrane Transfer	49
3.5	Prodrugs to Increase Oral Absorption	51
3.6	Active Transport	55
3.7	Models for Absorption Estimation	56
3.8	Estimation of Absorption Potential and other Computational Approaches	56
	References	57
4	Distribution	61
4.1	Membrane Transfer Access to the Target	62
4.2	Brain Penetration	63
4.2.1	Accumulation of Lower Permeability Compounds into the Brain	67
4.2.2	Distribution into Tumors	68
4.2.3	Volume of Distribution and Duration	70
4.2.4	Distribution and T_{\max}	77
	References	78
5	Clearance	81
5.1	The Clearance Processes	82
5.2	Role of Transport Proteins in Drug Clearance	83
5.3	Interplay Between Metabolic and Renal Clearance	87
5.4	Role of Lipophilicity in Drug Clearance	87
5.5	Active Metabolites	88
5.6	Balancing the Rate of Renal and Metabolic clearance and Potency	91
	References	101
6	Renal Clearance	103
6.1	Kidney Anatomy and Function	103
6.2	Lipophilicity and Reabsorption by the Kidney	105
6.3	Effect of Charge on Renal Clearance	106
6.4	Plasma Protein Binding and Renal Clearance	106
6.5	Balancing Renal Clearance and Absorption	108
6.6	Renal Clearance and Drug Design	109
	References	110

7	Metabolic (Hepatic) Clearance	111
7.1	Symbols	111
7.2	Function of Metabolism (Biotransformation)	112
7.3	Cytochrome P450	112
7.3.1	Catalytic Selectivity of CYP2D6	115
7.3.2	Catalytic Selectivity of CYP2C9	117
7.3.3	Catalytic Selectivity of CYP3A4	119
7.4	Other Oxidative Metabolism Processes	126
7.4.1	Aldehyde Oxidase	126
7.4.2	Flavin-Containing Monooxygenases	130
7.4.3	Monoamine Oxidases	133
7.5	Oxidative Metabolism and Drug Design	138
7.6	Nonspecific Esterases	138
7.6.1	Function of Esterases	138
7.6.2	Ester Drugs as Intravenous and Topical Agents	140
7.7	Prodrugs to Aid Membrane Transfer	142
7.8	Enzymes Catalyzing Drug Conjugation	144
7.8.1	Glucuronosyl- and Sulfotransferases	144
7.8.2	Methyl Transferases	147
7.8.3	Glutathione-S-Transferases	148
7.9	Stability to Conjugation Processes	149
7.10	Pharmacodynamics and Conjugation	152
	References	153
8	Toxicity	159
8.1	Toxicity Findings	160
8.1.1	Pharmacologic Mechanism-Based Toxicity	160
8.1.2	Chemotype-Dependent Toxicity	161
8.1.3	Metabolism-Induced Toxicity	164
8.2	Structure–Toxicity Analyses	167
8.3	Reactive Metabolite Screening in Drug Discovery	171
8.4	Structural Alerts/Toxicophores in Drug Design	173
8.5	Dealing with Reactive Metabolite Positives in Drug Discovery: Risk Assessment Strategies – Effect of Daily Dose	173
8.6	Dealing with Reactive Metabolite Positives in Drug Discovery: Risk Assessment Strategies – Competing Detoxication Pathways	182
8.7	Stratification of Toxicity	183
8.8	Toxicity Prediction: Computational Toxicology	183
8.9	Toxicogenomics	184
8.10	Pharmacogenomics	185
8.11	Enzyme Induction and Drug Design	186
8.12	Enzyme Inhibition and Drug Design	191
8.12.1	Quasi-Irreversible Inhibition	191

8.12.2	Irreversible CYP Inactivation via Apoprotein and/or Heme Covalent Modification	193
8.12.3	CYP Inhibition by Nitrogen-Containing Heterocycles	195
	References	202
9	Predicting Human Pharmacokinetics	209
9.1	Objectives of Predicting Human Pharmacokinetics	210
9.2	Allometric Scaling of Preclinical <i>In Vivo</i> PK Parameters	211
9.2.1	Volume of Distribution	211
9.2.2	Clearance	214
9.3	Prediction of Human PK Parameters Using <i>In Vitro</i> Data	220
9.3.1	Predicting Human Volume of Distribution from <i>In vitro</i> Data	220
9.3.2	Predicting Human Clearance from Human <i>In Vitro</i> Data	222
9.3.3	Species Scaling: Incorporating Differences in Metabolic Clearance	223
9.4	Elimination Half-Life	224
9.5	Moving Forward	224
	References	225
10	ADME Screening	229
10.1	The High-Throughput Synthesis and Screening Trend	230
10.2	The Concept of ADME Space	231
10.3	Drug Metabolism and Discovery Screening Sequences	233
10.4	Physicochemistry	234
10.4.1	Solubility	235
10.4.2	Ionization	236
10.4.3	Lipophilicity	236
10.4.4	Polar Surface Area	237
10.5	Absorption/Permeability	238
10.6	Metabolism, Induction, and Inhibition	239
10.7	Transporters	240
10.8	Protein Binding	242
10.9	Pharmacokinetics	243
10.10	<i>In silico</i> Approaches to ADME	243
10.10.1	QSAR Approaches to ADME	244
10.10.2	Theoretical Models for Predicting Metabolism	244
10.10.3	Physiologically-Based Pharmacokinetic Modeling	245
	References	246
	Index	251